Cleaner Air for Better Cardiac Biomarkers
Cardiometabolic Biomarker Improvements Associated With Reduction in Air Pollution Exposure Via Home Air Filtration
1 other identifier
interventional
48
1 country
1
Brief Summary
This pilot project is a randomized, double-blind, sham-controlled trial investigating whether in-home air pollution reductions using portable air cleaners (PACs) can decrease circulating concentrations of biomarkers of inflammation. Using both a targeted approach to study the established biomarker TNFa and an exploratory approach with a commercially available proteomic panel, the researchers will measure concentrations of biomarkers before and after four weeks of home PAC use in a cohort of 74 adults with hypertension recruited from NYU outpatient clinical settings. Participants will also track home blood pressure measurements for additional exploratory analysis of potential mediation of PAC-associated decreases in blood pressure by biomarker concentration changes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable cardiovascular-diseases
Started Aug 2022
Shorter than P25 for not_applicable cardiovascular-diseases
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2022
CompletedFirst Posted
Study publicly available on registry
May 18, 2022
CompletedStudy Start
First participant enrolled
August 11, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 24, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 24, 2023
CompletedResults Posted
Study results publicly available
December 6, 2024
CompletedDecember 6, 2024
October 1, 2024
1 year
May 12, 2022
July 26, 2024
October 18, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Percent Change in Circulating Concentration of Tumor Necrosis Factor Alpha (TNFα)
Circulating concentrations of TNFα will be measured using the Olink Explore 384 Cardiometabolic panel for this a priori specified analysis.
Baseline, Week 4
Secondary Outcomes (1)
Change in Indoor Particulate Matter < 2.5 um in Diameter (PM2.5) Concentration
Baseline, Week 4
Study Arms (2)
Portable Air Cleaner (PAC) group
EXPERIMENTALThis study will utilize a portable air cleaner as an intervention for the potential reduction of air pollution-associated inflammation. This commercially available device has no significant risks. The researchers plan to use a commercially available PAC with a "true HEPA" filter for the true arm.
Sham Portable Air Cleaner (PAC) group
SHAM COMPARATORFor the sham arm, the same model will be used with HEPA filter removed, and has identical appearance and sound. The researchers will use a PAC designed to filter air in rooms up to approximately 350 ft2, with minimal noise on the lowest setting.
Interventions
Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
Eligibility Criteria
You may qualify if:
- Participant is ≥18 years old
- Participant and members of household are reported to be non-smokers (defined as no household members are currently known to smoke cigarettes or use other tobacco products including e-cigarettes)
- Participant is to understand/speak English or Spanish
- Participant can understand study procedures and give informed consent
- Participant has stable hypertension: no medication changes in prior 30 days, systolic BP \<160 mm Hg and either ≥ 130 mm Hg without antihypertensive medications, or diagnosis of hypertension in medical records
- Able to measure home blood pressure twice daily
- Able to participate in video conference for home equipment setup
- Able to visit clinic for blood draws before and after the study period
- Do not intend to sleep anywhere outside of primary bedroom for more than 48 consecutive hours or a total of 7 days during the study period.
- Ability to lift, or access to assistance with lifting, 20 lb to set up PAC in bedroom.
You may not qualify if:
- Participants who are unable to provide a minimum of at least one blood pressure measurement per day
- Participants with average home blood pressure monitor readings of a systolic blood pressure (SBP) \>160 mmHg over any 10-day period during the study. This will be considered evidence of uncontrolled hypertension and will require study termination.
- Participants with known coronary artery disease
- Participants with known systemic inflammatory conditions (such as rheumatoid arthritis, inflammatory bowel disease, cancer)
- Participants currently taking any anti-inflammatory medications or medications that target inflammatory cytokines
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
NYU Langone Health
New York, New York, 10016, United States
MeSH Terms
Conditions
Results Point of Contact
- Title
- Sharine Wittkopp
- Organization
- NYU Langone Health
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan D Newman
NYU Langone Health
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 12, 2022
First Posted
May 18, 2022
Study Start
August 11, 2022
Primary Completion
August 24, 2023
Study Completion
August 24, 2023
Last Updated
December 6, 2024
Results First Posted
December 6, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
- Access Criteria
- The investigator who proposed to use the data. Upon reasonable request. Requests should be directed to Jonathan.Newman@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).